Home Nav
Nextech Invest Logo

Kai Wucherpfennig

Alfred Scheidegger

Kai Wucherpfennig MD PhD is Professor and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School.
Prof. Wucherpfennig’s research focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment drawing insights for the development of next-generation cancer immunotherapies. He has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation. He received his MD and PhD degrees from the University of Goettingen and completed post-doctoral work in immunology at Brigham & Women’s Hospital, Harvard Medical School, and Harvard College. Wucherpfennig serves as an advisor to a number of immuno-oncology companies and since 2015 is an exclusive scientific consultant of Nextech Invest. 

 

Swiss Biotech Day

04.05.2017

Basel

  • 20.04.2017

    Jounce Therapeutics initiates Phase 2 portion of ICONIC...

  • 19.04.2017

    Kura Oncology granted U.S. patent for clinical-stage...

  • 10.04.2017

    Tracon awarded 'Most Innovative Trial Design' for Phase...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close